Hepatology News

The FDA has updated the label indication for Livmarli for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the patient population to include infants aged 12 months and older.

Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.

Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.

In a dose-dependent manner, fazirsiran reduced serum and liver concentrations of Z-AAT and also improved histological measures in patients with homozygous ZZ alpha-1 antitrypsin deficiency-associated liver disease, according to data.

NEW YORK — In this Healio Video Perspective from the American Psychiatric Association Annual Meeting, Stefanie Simmons, MD, FACEP, chief medical officer of the Dr. Lorna Breen Heroes’ Foundation, discusses the Frontline Connect toolkit.

The Savings on a Valuable Education (SAVE) plan was introduced in 2023 by the Biden Administration and replaces the Revised Pay As You Earn (REPAYE) program. SAVE continues to evolve with new benefits for student loan borrowers.

Tenofovir alafenamide was safe and maintained virological response in patients with chronic hepatitis B virus infection and renal or hepatic impairment who switched from tenofovir disoproxil fumarate or other antivirals, according to data.

Substitution of just one meat-based meal with a vegetarian or vegan alternative reduced serum ammonia levels for up to 3 hours and improved metabolites in patients with cirrhosis who follow a Western meat-based diet, researchers reported.

U.S. News & World Report announced its 2024-2025 Best Hospitals rankings Tuesday.

In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that, despite the boom in glucagon-like peptide-1 agonists for diabetes and weight loss, its role in the treatment of liver disease is still up for debate.